A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 43
- Population
- ALL · 55 Years
- Duration
- 2019-06-27 to 2023-11-01
- Intervention
- BI 836880
- Comparator
- Not reported
- Outcomes measured
- SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — From drug administration until the end of tr…; MRD-part: Number of Participants With Drug Related Adverse Events (AEs) — From first drug administration until the end…; SRD-part: Number of Participants With Drug Related Adverse Events (AEs) — From drug administration until the end of tri…; SRD-part: Number of Participants With Any Ocular Adverse Events in the Study Eye — From drug administration until the e…; MRD-part: Percentage Change From Baseline in Central Subfield Thickness (CSFT) in the Study Eye at Week 12 — At baselin…; MRD-part: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 12 — At baseline and at…; MRD-part: Time to Recurrence in the Study Eye From Last Administration at Each Visit — From last drug administration at…; MRD-part: Number of Participants With Any Ocular Adverse Events in the Study Eye — From first drug administration until…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.